Nisa Investment Advisors LLC Buys 14,774 Shares of Royalty Pharma PLC $RPRX

Nisa Investment Advisors LLC lifted its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 60.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 39,174 shares of the biopharmaceutical company’s stock after buying an additional 14,774 shares during the period. Nisa Investment Advisors LLC’s holdings in Royalty Pharma were worth $2,286,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Blue Trust Inc. raised its position in Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 437 shares during the last quarter. CoreCap Advisors LLC lifted its stake in Royalty Pharma by 89.2% during the 2nd quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 413 shares in the last quarter. Bessemer Group Inc. boosted its holdings in Royalty Pharma by 34.7% during the 1st quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 282 shares during the last quarter. IFP Advisors Inc boosted its holdings in Royalty Pharma by 263.3% during the 2nd quarter. IFP Advisors Inc now owns 1,188 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 861 shares during the last quarter. Finally, Oslo Pensjonsforsikring AS purchased a new position in Royalty Pharma during the 1st quarter worth $95,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insider Activity

In other Royalty Pharma news, EVP Marshall Urist sold 4,126 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the transaction, the executive vice president directly owned 270,401 shares of the company’s stock, valued at approximately $15,826,570.53. This trade represents a 27.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 208,252 shares of company stock worth $12,324,407. Insiders own 18.84% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on RPRX. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 26th. TD Cowen raised their price target on shares of Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. The Goldman Sachs Group restated a “buy” rating and set a $66.00 price target on shares of Royalty Pharma in a report on Thursday, August 6th. Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, September 14th. Finally, Morgan Stanley increased their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Eight research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $61.57.

Royalty Pharma Stock Up 0.2%

RPRX stock opened at $63.86 on Friday. The stock has a market cap of $36.72 billion, a P/E ratio of 44.04, a P/E/G ratio of 1.75 and a beta of 0.42. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 0.88. The stock’s fifty day simple moving average is $59.83 and its two-hundred day simple moving average is $56.22. Royalty Pharma PLC has a 1-year low of $35.92 and a 1-year high of $64.38.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.05. The firm had revenue of $674.14 million during the quarter, compared to analyst estimates of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. Analysts expect that Royalty Pharma PLC will post 5.29 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $0.2350 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date is Friday, November 13th. Royalty Pharma’s dividend payout ratio (DPR) is 64.83%.

About Royalty Pharma

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.